secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-08-13T20:20:20+00:00
Accession:  0001493152-26-037794
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Q2 net loss $2.6M; completes Cy Biopharma acquisition adding CY200, $77M funding
--------------------------------------------------------------------------------

- Completed acquisition of Cy Biopharma on Aug 6, 2026, adding CY200 (Orphan Drug-designated for CRPS) as lead asset; up to $77M in new funding.
- Q2 2026 net loss $2.6M vs $1.7M; cash $0.7M at June 30, 2026 vs $4.3M at Dec 31, 2025.
- Post-quarter-end acquisition and financings provided ~$31M net cash; runway into late 2027, second tranche up to $38.6M on milestones.
- R&D expenses $2.5M (up from $1.9M); federal grants $1.2M; NIDA grant third year awarded, total $26M over six years.
- Taiwan patent for MPAR through 2042; PF614-301 Phase 3 trial ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226037794/0001493152-26-037794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226037794/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer